This content is restricted.
Brief
"On "14/11/2024", the "European Medicines Agency (EMA)" issued an update regarding "Leqembi recommended for treatment of early Alzheimer’s disease". Leqembi's benefits in slowing down progression of symptoms outweigh its risks, particularly ARIA-related side effects, in patients with one or no ApoE4 copy.
Highlights content goes here...
This content is restricted.

RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested